Liquid Biopsy For Cancer Diagnostics Industry Growth Expected to Reach $19.32 Billion by 2029 at a CAGR of 15.7% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Liquid Biopsy For Cancer Diagnostics Market Growth in 2025?
In recent times, the market size for liquid biopsy in cancer diagnostics has seen swift growth. The projections show that it will increase from $9.23 billion in 2024 to $10.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.8%. The significant growth in the past can be related to the progress in genomic studies, escalating awareness about the perks of liquid biopsy, rising incidence of cancer, a surge in the requirement for non-invasive cancer diagnosis, and the broadening of precision medicine initiatives.
What Is the Forecast for the Liquid Biopsy For Cancer Diagnostics Market Size Through 2029?
The market for liquid biopsy in cancer diagnostics is predicted to witness rapid growth in the upcoming years, reaching $19.32 billion by 2029 with a compound annual growth rate (CAGR) of 15.7%. The acceleration during the forecast period can be credited to the incorporation of liquid biopsy in standard cancer diagnostics, the utilization of liquid biopsy in detecting cancer early, the broadening of cancer screening programs, an intensified emphasis on personalized medicine in oncology, and augmented financing for liquid biopsy research. Emerging trends during the forecast period comprise the development of multi-omics liquid biopsy methods, the inclusion of artificial intelligence in liquid biopsy analysis, the expansion of liquid biopsy applications beyond oncology, the creation of blood-based biomarkers for cancer, and the customization of liquid biopsy assays designed for specific types of cancer.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp
What are the Key Market Players in Liquid Biopsy For Cancer Diagnostics Market and How They’re Evolving?
Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC
What Are the Primary Growth Drivers in the Liquid Biopsy For Cancer Diagnostics Market?
The liquid biopsy for cancer diagnostics market is set to grow due to the increasing prevalence of cancer. Cancer, a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells to other organs or nearby tissues, necessitates diagnostic procedures such as early or recurring tumor detection, patient-specific risk evaluation, and treatment monitoring. The liquid biopsy method provides comprehensive and current data about tumor cell changes, therapeutic targets, and treatment resistance mechanisms by capturing the entirety of the disease, as it traces tumor cells or their byproducts released from all metastatic or primary tumor locations. As reported by the National Cancer Institute, a US-based government body, in May 2024, approximately 18.1 million people in the US had survived cancer. This number is anticipated to climb to 22.5 million by 2032. It is predicted that, by 2040, new cancer cases will increase to an annual figure of 29.9 million, while cancer-related deaths are expected to rise to 15.3 million. Thus, the escalating prevalence of cancer is fuelling the growth of the liquid biopsy for cancer diagnostics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp
What Are the Leading Segments in the Global Liquid Biopsy For Cancer Diagnostics Industry?
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
What Are the Key Market Trends in the Liquid Biopsy For Cancer Diagnostics Industry?
Emergence of product innovations is a significant trend observed in the liquid biopsy for cancer diagnostics market. To solidify their presence in the market, key companies in this sector are focusing their efforts on developing innovative products. Take for example BostonGene, a biomedical software company based in the US. In June 2023, they rolled out new liquid biopsy solutions for the detection of clinically significant gene changes. This expanded testing portfolio is expected to accelerate the development of new assays, analytical instruments, and procedures for delivering precision medicine to patients. These solutions will leverage a variety of AI-powered molecular and immunological profiling techniques to assess tumors, microenvironments, and host immunity. Furthermore, it aids immunotherapy treatment, provides information on a patient’s immune-associated conditions, and tracks the progression of the disease and response to treatment.
Access The Full Report Here:
What Is the Regional Outlook for the Liquid Biopsy For Cancer Diagnostics Market?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205
This Report Delivers Insight On:
1. How big is the liquid biopsy for cancer diagnostics market, and how is it changing globally?
2. Who are the major companies in the liquid biopsy for cancer diagnostics market, and how are they performing?
3. What are the key opportunities and risks in the liquid biopsy for cancer diagnostics market right now?
4. Which products or customer segments are growing the most in the liquid biopsy for cancer diagnostics market?
5. What factors are helping or slowing down the growth of the liquid biopsy for cancer diagnostics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
